Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 2Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Prostatic Neoplasms 80Breast Neoplasms 39Neoplasms 6Neoplasm Metastasis 4Leiomyoma 2Infertility 2Breast Neoplasms, Male 2Stage I Prostate Adenocarcinoma AJCC v7 1Sexual Dysfunction, Physiological 1Sarcopenia 1Salivary Gland Neoplasms 1Recurrence 1Primary Dysautonomias 1Patient Compliance 1Ovarian Neoplasms 1Osteoporosis 1Osteitis Deformans 1Lymphatic Metastasis 1Kidney Diseases 1Hypertension 1Hyperlipidemias 1Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer 1Hodgkin Disease 1Hereditary Sensory and Autonomic Neuropathies 1Hemorrhage 1Fallopian Tube Neoplasms 1Castrate Sensitive Prostate Cancer 1Carcinoma, Ovarian Epithelial 1Bulbo-Spinal Atrophy, X-Linked 1Advanced Prostate Cancer 1

Interventions

Cetuximab 11Cisplatin 10Radiotherapy 8Docetaxel 8Erlotinib Hydrochloride 7Paclitaxel 6Gemcitabine 6Chemotherapy, Adjuvant 6Immunohistochemistry 5Sorafenib 4Radiosurgery 4Carboplatin 4Capecitabine 4Biopsy 4sargramostim 3Vorinostat 3Trastuzumab 3Surgical Procedures, Operative 3Radiotherapy, Intensity-Modulated 3Nivolumab 3N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 3Lapatinib 3Irinotecan 3Filgrastim 3Doxorubicin 3Bevacizumab 3ixabepilone 2aldesleukin 2Taxes 2SS1(dsFv)PE38 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Salivary Gland Neoplasms × Goserelin × Clear all
NCT05694819 2026-04-08

Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

National Cancer Center Hospital East

Phase 2 Completed
57 enrolled
Head & Neck

Salivary Gland Neoplasms, Bulbo-Spinal Atrophy, X-Linked

Data powered by HemOnc (CC BY 4.0) Colophon âš¡